Chronic Obstructive Pulmonary Disease Market Size in the 7MM is projected to grow at a CAGR of 6.3% by 2034, estimates DelveInsight

DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as Chronic Obstructive Pulmonary Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore Chronic Obstructive Pulmonary Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Chronic Obstructive Pulmonary Disease Market Report
• On December 15, 2025- Sanofi initiated a Phase 2/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.
• On December 12, 2025- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. announced a Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
• The total number of diagnosed prevalent cases of COPD in the 7MM was about ~31 million in 2024.
• In the US, cigarette smoking is the primary cause of COPD, with significantly higher rates observed in both current and former smokers compared to those who never smoked. Additionally, individuals with higher family incomes tend to have lower COPD prevalence, indicating a link between socioeconomic status and disease risk.
• In comparison to the US, in EU4 and the UK, COPD continues to be more prevalent among men, largely reflecting historical patterns of higher smoking rates and occupational exposures in male populations. Although the gender gap has narrowed over time with rising diagnoses in women, men still represent a larger share of the COPD burden.
• In EU4 and the UK, COPD cases were highest in Germany in 2024, whereas the minimum number of cases was in the UK, cases in 2024.
• The US accounted for the highest GOLD 2 cases (~8.2 million), which were followed by GOLD 3 (~4.3 million) cases, compared to other countries in the 7MM.
• In 2024, chronic bronchitis accounted for the highest share of COPD cases in EU4 and the UK, comprising ~6.42 million cases.
• In Japan, there is a significant gap between the estimated number of COPD patients and those receiving treatment, indicating widespread underdiagnosis; this highlights the high unmet need to enhance early detection and management efforts. Japan observed the maximum number of cases from the age group 65-74 years (~283,000) in 2024.
• The leading Chronic Obstructive Pulmonary Disease Companies such as AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.
• Promising Chronic Obstructive Pulmonary Disease Therapies such as BFF MDI 320/9.6 μg, QVA149, NVA237, Depemokimab, PF-00610355, Astegolimab, Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, and others.

Strategize your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Overview
Chronic Obstructive Pulmonary Disease (COPD) is a progressive and long-term respiratory disorder characterized by persistent airflow limitation that is not fully reversible and worsens over time, primarily due to chronic inflammation of the airways and lung tissue. It encompasses conditions such as chronic bronchitis, marked by excessive mucus production and cough, and emphysema, which involves destruction of the alveoli leading to reduced gas exchange.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases
• Subtype-specific Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation
• Treatment eligible pool

Visit for more about Chronic Obstructive Pulmonary Disease Prevalence @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Chronic Obstructive Pulmonary Disease Therapies
NUCALA: GSK Pharmaceuticals
NUCALA (mepolizumab) is a fixed-dose biologic therapy approved for subcutaneous injection to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), and recently, eosinophilic phenotype COPD. NUCALA is available as prefilled syringes, autoinjectors, and powder for injection, designed for easy and flexible use by healthcare providers or patients after training. The medication requires refrigeration and is intended for single-patient use. This delivery system supports convenient, at-home treatment of eosinophilic respiratory diseases. In May 2025, GSK announced that the US FDA approved NUCALA for use in adults with COPD. The approval was based on data from the METREX and METREO Phase III trials, which showed a statistically significant reduction in moderate and severe exacerbations in patients with elevated eosinophil counts who were already on maximum inhaled therapies. According to GSK's 2025 Q1 presentation, the filing for NUCALA in Europe is planned for 2026.

DUPIXENT: Regeneron Pharmaceuticals/Sanofi
DUPIXENT (dupilumab), developed by Regeneron Pharmaceuticals/Sanofi, is primarily developed for the treatment of adult patients with uncontrolled COPD, which is administered SC. DUPIXENT is the first biologic to be approved in Europe, changing the entire pursuit of the market from now on. Recently, DUPIXENT has achieved a significant milestone with its approval as the first-in-world treatment for adults with uncontrolled COPD characterized by elevated blood eosinophils. This decision follows two pivotal Phase III studies, which demonstrated that DUPIXENT effectively reduced exacerbations, enhanced lung function, and improved health-related quality of life. In September 2024, the US FDA approved DUPIXENT (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. DUPIXENT is the first biologic medicine approved in the US to treat these patients. Sanofi and Regeneron have jointly developed DUPIXENT under a global collaboration agreement. Dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by Type 2 inflammation. Apart from its existing approved uses, Sanofi and Regeneron are investigating dupilumab in Phase III trials for various conditions influenced by Type 2 inflammation or allergic reactions.

OHTUVAYRE: Verona Pharma
OHTUVAYRE is a first-in-class selective dual inhibitor of the enzymes PDE3 and PDE4 that combines bronchodilator and nonsteroidal anti-inflammatory effects in one molecule. OHTUVAYRE met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD. Ensifentrine has potential applications for development in noncystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.

Emerging Chronic Obstructive Pulmonary Disease Therapies

• Depemokimab: GSK
Depemokimab is the first ultra-long-acting biologic to be evaluated in a Phase III trial with a binding affinity and high potency for IL-5, enabling 6-month dosing intervals for patients. IL-5 is known to be a key cytokine (protein) in Type 2 inflammation. As per GSK's Q1 presentation, the Phase III clinical trial of depemokimab is expected to start in H2 2025.

• Itepekimab: Regeneron Pharmaceuticals/Sanofi
Itepekimab is a fully human mAb that binds to and inhibits IL-33, an initiator and amplifier of broad inflammation in COPD. IL-33 is thought to be involved in different types of inflammation and is particularly elevated in the lungs of former smokers. Sanofi and Regeneron are jointly developing Itepekimab under a global collaboration agreement.

• TEZSPIRE (tezepelumab): AstraZeneca/Amgen
TEZSPIRE is a first-in-class human mAb that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic, and other types of epithelial-driven inflammation associated with severe asthma and other inflammatory diseases.

For more information, visit Chronic Obstructive Pulmonary Disease Medication and Companies @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Market Outlook
The Chronic Obstructive Pulmonary Disease market is expected to grow steadily over the coming years, driven by rising disease prevalence, aging populations, and increased awareness and diagnosis. While traditional inhaled therapies like LABAs, LAMAs, and ICS remain the mainstay, the landscape is evolving with the introduction of novel agents, including biologics and dual-action molecules like PDE inhibitors.

Chronic Obstructive Pulmonary Disease Companies
AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.

Scope of the Chronic Obstructive Pulmonary Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Obstructive Pulmonary Disease Companies- AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.
• Chronic Obstructive Pulmonary Disease Therapies- BFF MDI 320/9.6 μg, QVA149, NVA237, Depemokimab, PF-00610355, Astegolimab, Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, and others.
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers
• Chronic Obstructive Pulmonary Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Obstructive Pulmonary Disease Unmet Needs, KOL's views, Analyst's views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Chronic Obstructive Pulmonary Disease Treatment Market @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Chronic Obstructive Pulmonary Disease Market Report Introduction
3. Executive Summary
4. Chronic Obstructive Pulmonary Disease Market Overview at a Glance
5. Key Chronic Obstructive Pulmonary Disease Events
6. Chronic Obstructive Pulmonary Disease Epidemiology and Market Methodology
7. Chronic Obstructive Pulmonary Disease Background and Overview
8. Chronic Obstructive Pulmonary Disease Treatment and Management
9. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population
10. Chronic Obstructive Pulmonary Disease Patient Journey
11. Chronic Obstructive Pulmonary Disease Marketed Drugs
12. Chronic Obstructive Pulmonary Disease Discontinued Product
13. Chronic Obstructive Pulmonary Disease Emerging Drugs
14. Chronic Obstructive Pulmonary Disease: Seven Major Market Analysis
15. Chronic Obstructive Pulmonary Disease Unmet Needs
16. Chronic Obstructive Pulmonary Disease SWOT Analysis
17. Chronic Obstructive Pulmonary Disease KOL Views
18. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement
19. Appendix
20. Delveinsight Capabilities
21. Disclaimer
22. About Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.